Overview

A Multi-Center Study to Evaluate the Efficacy and Safety of KX01 Ointment 1% on Actinic Keratosis on Face or Scalp

Status:
Active, not recruiting

Trial end date:
2023-07-31

Target enrollment:

Participant gender:

Summary

This Phase III study is designed to evaluate the efficacy and safety of KX01 Ointment in adult participants when applied to an area of skin containing more than 1, clinically typical Actinic Keratosis (AK) lesions on the face or scalp.

Phase:

Phase 3

Details

Lead Sponsor:

PharmaEssentia

Collaborator:

PharmaEssentia Japan K.K.